| Patient | Elvis Presley |
|---|---|
| Date of birth | 1935-01-08 |
| Identifiers | MRN HR-ML003-SYN-TD; SSN (made up) 000-03-4417 |
| Document date | 1974-07-17 |
| Author | Coleman Ashby-Nakagawa, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
One-week review, seen the same day by addiction medicine. [S]
Mr. Presley returns one week after intake and is seen by Dr. Eberhardt-Mensah of addiction medicine on the same day. He has taken only the medicines this clinic prescribed, from one pharmacy, and brought the remaining tablets. As agreed, he took his last hydromorphone about 18 hours ago and his last oxycodone about 20 hours ago so that buprenorphine could be started today; he has yawning, a runny nose, aching legs, gooseflesh and loose stools. He took his usual diazepam and alprazolam last night. His in-laboratory sleep study three days ago showed moderate obstructive sleep apnea. His home blood pressure readings over six days, after stopping phentermine, averaged 146/94. His bowels opened twice this week on polyethylene glycol and senna. He has kept his firearms locked and the naloxone in the house. He says he is ready to start treatment before his engagement. [S]
| Element | Detail |
|---|---|
| Last full-agonist opioid | Hydromorphone 18 hours ago; oxycodone 20 hours ago |
| Withdrawal | Yawning, rhinorrhea, aching, gooseflesh, loose stools; COWS 12 (moderate) |
| Sleep study | Apnea-hypopnea index 26; central apnea index 4; nadir 80% |
| Home blood pressure | Average 146/94 over six days |
| Bowels | Twice this week |
| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Aching and chills from withdrawal |
| Gastrointestinal | Positive | Loose stools today; mild cramps |
| Eyes | Positive | Watery eyes; no pain or halos |
| Psychiatric | Positive | Anxious about withdrawal; no thoughts of suicide or self-harm |
4 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Hydromorphone 4 mg oral tablet, prescribed elsewhere as one tablet every four to six hours as needed for back and neck pain; taking about five a day (20 mg, 100 MME); continued by this clinic only, at the verified dose and seven days at a time, until the addiction medicine consultation | Up to five tablets a day; seven-day supply | Oral route | 1974-07-10 to 1974-07-17 | completed | S |
| Oxycodone 10 mg and acetaminophen 325 mg oral tablet, prescribed by a second prescriber; taking about three a day (45 MME); continued by this clinic only, seven days at a time, until the consultation | Up to three tablets a day; seven-day supply | Oral route | 1974-07-10 to 1974-07-17 | completed | S |
| Diazepam 10 mg oral tablet, one tablet three times daily, prescribed elsewhere for anxiety; continued by this clinic only, seven days at a time | One tablet three times daily; seven-day supply | Oral route | 1974-07-10 to 1974-07-17 | completed | S |
| Alprazolam 1 mg oral tablet, up to three a day as needed, prescribed by a fourth prescriber while on tour; continued by this clinic only, at the verified dose, seven days at a time | Up to three tablets a day; seven-day supply | Oral route | 1974-07-10 to 1974-07-17 | completed | S |
| Phentermine 37.5 mg oral tablet each morning, prescribed by a weight clinic; stopped today because of high blood pressure and his glaucoma | Stopped | Oral route | 1974-07-10 to 1974-07-10 | completed | S |
| Latanoprost 0.005% eye drops, one drop in each eye at bedtime, prescribed by his ophthalmologist | One drop in each eye at bedtime | Ophthalmic route | 1974-07-10 | active | S |
| Naloxone 4 mg nasal spray, one spray into one nostril for a suspected overdose, repeated in the other nostril after two to three minutes if needed; two-pack, with a second for the tour bag | One spray for a suspected overdose; call 911 | Nasal route | 1974-07-10 | active | S |
| Polyethylene glycol 3350, 17 g powder in a glass of water once daily | 17 g in water once daily | Oral route | 1974-07-10 | active | S |
| Senna 8.6 mg oral tablet, two tablets at bedtime | Two tablets at bedtime | Oral route | 1974-07-10 to 1974-08-07 | completed | S |
| Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily, which may be split into one film twice daily; started in the office at the consultation; seven-day supplies at first, from this clinic only | Two films once daily, or one film twice daily | Sublingual route | 1974-07-17 | active | S |
| Diazepam 10 mg oral tablet, one tablet four times daily (40 mg a day), replacing both diazepam 10 mg three times daily and alprazolam; held steady until buprenorphine is stable | One tablet four times daily; seven-day supply | Oral route | 1974-07-17 to 1974-08-07 | completed | S |
| Amlodipine 5 mg and valsartan 160 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1974-07-17 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1974-07-17 | Body height | 183 | cm | S |
| 1974-07-17 | Body weight | 108.6 | kg | S |
| 1974-07-17 | Body mass index (BMI) [Ratio] | 32.4 | kg/m2 | S |
| 1974-07-17 | Systolic blood pressure | 146 | mm[Hg] | S |
| 1974-07-17 | Diastolic blood pressure | 94 | mm[Hg] | S |
| 1974-07-17 | Heart rate | 102 | /min | S |
| 1974-07-17 | Respiratory rate | 18 | /min | S |
| 1974-07-17 | Body temperature | 37 | Cel | S |
| 1974-07-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
Vital signs recorded on 1974-07-17; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Restless, yawning; blood pressure 146/94, pulse 102, temperature 37.0 °C |
| Eyes | Pupils 5 mm and reactive; lacrimation |
| Skin | Piloerection; sweating; no injection marks |
| Neurological | Mild tremor of the outstretched hands; alert and oriented |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Fatigue, weight gain of about 14 kg in two years, constipation with a bowel movement every five to seven days, loud snoring with daytime sleepiness, and high blood pressure readings, in a man taking two opioids, two benzodiazepines and an appetite suppressant from five prescribers; under evaluation with addiction medicine, a sleep study and home blood pressure readings | resolved | confirmed | R53.83 | S — Synthetic presenting problem anchored to the documented prescribed drugs and weight gain; superseded when the consultation and tests made the diagnoses. |
| Obesity, class 1 (BMI 32.5), with prediabetes (hemoglobin A1c 5.8%); recorded without stigma; weight gain began with long touring schedules, night eating after shows and an appetite suppressant that stopped working | active | confirmed | E66.811 | S — Synthetic modern diagnosis anchored to his documented weight gain. |
| Glaucoma secondary to steroids, both eyes, mild stage, after an acute angle-closure episode treated years ago; intraocular pressure controlled on latanoprost under his ophthalmologist; anticholinergic and sympathomimetic drugs to be avoided | active | confirmed | H40.63X1 | S — Synthetic modern diagnosis anchored to his documented glaucoma and the retrospective interpretation of it as steroid-induced; not a claim about his real eyes. |
| Opioid use disorder, severe, with prescription opioids from more than one prescriber (seven DSM-5-TR criteria, tolerance and withdrawal counted because the opioids were not taken as prescribed); on buprenorphine from the consultation; synthetic modern episode linked to his documented withdrawal from narcotic drugs and prescribed painkillers | active | confirmed | F11.20 | S — Synthetic modern diagnosis made at the addiction medicine consultation; person-first language; not a claim about his real diagnosis. |
| Sedative, hypnotic, or anxiolytic use disorder (benzodiazepines), moderate (five DSM-5-TR criteria), with two benzodiazepines from two prescribers; combined into diazepam and tapering slowly; synthetic modern episode linked to his documented prescribed sedatives | active | confirmed | F13.20 | S — Synthetic modern diagnosis made at the consultation; not a claim about his real diagnosis. |
| Hypertension, stage 2, confirmed by a home average of 146/94 a week after stopping phentermine; ECG and urine albumin normal | active | confirmed | I10 | S — Synthetic modern diagnosis confirmed with home readings, anchored to his documented hypertension. |
| Obstructive sleep apnea, moderate (apnea-hypopnea index 26 an hour, central apnea index 4, oxygen nadir 80% on in-laboratory polysomnography), worsened by opioids and benzodiazepines; on CPAP | active | confirmed | G47.33 | S — Synthetic modern diagnosis from a synthetic sleep study. |
| Opioid-induced constipation (Rome IV), improving after the change to buprenorphine; no alarm features | active | confirmed | K59.03 | S — Synthetic modern diagnosis anchored to his documented blockage of the colon; not a claim about megacolon. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Medication safety | Buprenorphine dose, withdrawal symptoms, cravings and other opioid use | Every visit; weekly contact in the first month | Completed today | COWS 12 before the first dose; 8 mg given in the office; 16 mg a day from tomorrow |
| Medication safety | Prescription drug monitoring program check | Before every controlled-substance prescription | Completed today | Only this clinic's seven-day prescriptions since intake; the earlier prescribers notified that this clinic now prescribes |
| Laboratory | Urine drug test, including buprenorphine metabolite and fentanyl | At the start of treatment, then about monthly while doses are changing | Completed today | Point-of-care test today: hydromorphone, oxycodone and benzodiazepines present; fentanyl and other drugs absent (narrative) |
| Medication safety | Naloxone on hand and people taught to use it | Every visit | Completed today | Two-pack at home and one in the tour bag; two friends trained |
| Medication safety | Diazepam dose, withdrawal symptoms (anxiety, insomnia, tremor, sweats) and taper pace | Every two to four weeks during the taper | Completed today | Diazepam 30 mg and alprazolam 3 mg a day combined into diazepam 40 mg a day; no taper step during the buprenorphine start |
| Survey | Suicide-risk review, safety plan, means safety (locked medicines and firearms) and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or self-harm; firearms locked; medicines in a locked box; 988 in his phone |
| Survey | Mood (PHQ-9) and anxiety (GAD-7) | At baseline, four to six weeks after a change in treatment, then at each review | Up to date | PHQ-9 8 and GAD-7 9 at intake; repeat at the next visit |
| Examination | Office and home blood pressure (target below 130/80) | Every visit | Completed today | Office 146/94 in withdrawal; home average 146/94; treatment started |
| Imaging | Electrocardiogram at diagnosis of hypertension | At diagnosis | Up to date | Normal at intake, QTc 436 ms |
| Laboratory | Potassium and creatinine after starting an angiotensin receptor blocker | Two to four weeks after starting, then every six months | Due | Valsartan started today; check at the next visit |
| Examination | Weight and BMI | Every visit | Completed today | 108.6 kg, BMI 32.4 |
| Survey | CPAP adherence (device data) and sleepiness (Epworth, recorded as narrative) | Within the first 30 to 90 days, then at each review | Due | Polysomnogram three days ago; CPAP starts this week |
| Self-management | Bowel frequency, straining and alarm features | Every visit | Completed today | Twice this week; no blood, weight loss or vomiting |
| Examination | Glaucoma: drop adherence, eye symptoms, medicines that raise eye pressure or close the angle, and ophthalmology follow-up | Every visit; ophthalmology every three to six months while recently controlled | Completed today | Latanoprost nightly; phentermine and the nonprescription diphenhydramine sleep aid stopped; no eye pain or halos; ophthalmology visit in September |
| Referral | Addiction medicine consultation | At diagnosis | Completed today | Seen by Dr. Eberhardt-Mensah today |
| Self-management | Touring plan: one named pharmacy, video visits while away, CPAP and naloxone in the tour bag, no dose change in the week before an engagement | Before each engagement or tour | Up to date | Las Vegas engagement in five weeks; plan to be written at the next visit |
Goal progress:
Guideline basis: CDC Clinical Practice Guideline for Prescribing Opioids for Pain — United States, 2022 (2022); The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020); Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025); Prescription Drug Monitoring Programs (PDMPs) (2026); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); Treatment of Adult Obstructive Sleep Apnea with Positive Airway Pressure: An American Academy of Sleep Medicine Clinical Practice Guideline (2019); American Gastroenterological Association Institute Guideline on the Medical Management of Opioid-Induced Constipation (2019); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024)
Follow-up: Phone check tomorrow and weekly contact. Three-week review. Call or use naloxone and 911 for heavy sedation or slow breathing. Next scheduled visit 1974-08-07: three-week review on buprenorphine: withdrawal and cravings, the first benzodiazepine taper step, blood pressure treatment, CPAP, constipation and weight, and planning for a Las Vegas engagement. [S]